Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
BONESUPPORT HOLDING AB ( (SE:BONEX) ) has shared an update.
Bonesupport Holding AB reported another quarter of robust expansion, with first-quarter 2026 net sales rising 14 percent year-on-year to SEK 324 million, or 31 percent at constant exchange rates, driven by 16 percent growth in the U.S. segment and 9 percent in Europe and Rest of World. Profitability continued to strengthen, as the adjusted operating result more than doubled to SEK 84.9 million, gross margin remained above 92 percent, and earnings per share rose sharply, supported by solid operating cash flow and a strong net cash position.
Clinical and reimbursement developments are reinforcing Bonesupport’s position in orthopaedic infection management, with two U.S.-based clinical publications on CERAMENT G in trauma-related bone infection and infection prevention released during the quarter. After the period, proposed U.S. CMS changes would improve reimbursement and coding for CERAMENT G and CERAMENT V and introduce NTAP support for CERAMENT V, which, if implemented, could significantly enhance the company’s revenue potential and market adoption in complex orthopaedic infection surgery.
More about BONESUPPORT HOLDING AB
Bonesupport Holding AB is a medical technology company specializing in injectable bone graft substitutes used in orthopaedic procedures, particularly for bone infections and trauma cases. The group has a strong commercial focus on the U.S. market, complemented by its Europe and Rest of World segment, and generates high-margin revenue from its CERAMENT product portfolio.
Average Trading Volume: 329,162
Technical Sentiment Signal: Buy
Current Market Cap: SEK17.36B
For detailed information about BONEX stock, go to TipRanks’ Stock Analysis page.